

Trajan Scientific and Medical

Global Corporate Headquarters 7 Argent Place, Ringwood Victoria 3134, Australia Tel: +61 (0) 3 9837 4200 www.trajanscimed.com

Trajan Group Holdings Limited ACN 152 617 706

ASX RELEASE

Trajan Presents at Canaccord Growth Conference, Boston, USA

7 August 2023 – Global analytical science and device company Trajan Group Holdings Limited (**ASX: TRJ**) (**Trajan** or **the Company**) is presenting at the Canaccord Growth Conference in Boston, USA.

The Conference, running from 7-10 August, attracts institutional investors from across the globe and showcases companies in high stages of business growth and opportunities. There is a high level of interest in Trajan. Trajan CEO and Managing Director Stephen Tomisich is meeting with investors throughout the conference.

Trajan has a prominent operational and commercial footprint in North America with this region currently representing 53% of revenues, with four manufacturing facilities (Louisville, Bethel, Raleigh, and Austin) and operations in Torrance, Austin, and Louisville. The Company's US customer base includes large scientific Original Equipment Manufacturers (OEMs), channel partners and direct customers in the life science, pharmaceutical, research and analytical laboratories segments.

Over the last decade Trajan has achieved significant business growth including the acquisition of 12 businesses, of which HD Examiner (2023), Chromatography Research Supplies (2022), Neoteryx (2021), LEAP PAL Parts, (2021), Soltec (2018), Epic Extrusion (2016), and Leap Technologies (2016) were all US based and owned companies.

Regarding the upcoming sessions Mr. Tomisich said: "North America is an important market for Trajan, and it currently represents more than half of our business with a significant operational and manufacturing footprint and high concentration of customers. We are looking forward to raising our profile with US and international investors who have a deep and mature understanding of the analytical workflow and scientific equipment industries and the growth potential that sits within them."

Authorised for ASX release by the Disclosure Committee of Trajan Group Holdings Limited.

END



Contact:

Investors
Rebecca Wilson
WE Communications
investorrelations@trajanscimed.com

Media
Amy Miller
WE Communications
amymi@we-worldwide.com

About Trajan

Trajan is a global developer and manufacturer of analytical and life sciences products and devices founded to enable science that benefits people by enriching personal health through scientific tools and solutions. These products and solutions are used in the analysis of biological, food, and environmental samples. Trajan has a portfolio and pipeline of new technologies which support the move towards decentralised, personalised data-based healthcare.

Trajan is a global organisation of more than 650 people, with seven manufacturing sites across the US, Australia, Europe and Malaysia, and operations in Australia, the US, Asia, and Europe.